Topic:

M&A

Latest Headlines

Latest Headlines

Deal-happy Actavis eyes Spain's Almirall for European growth: Bloomberg

Just one month after announcing a $66 billion pact to buy Allergan, Actavis is eyeing Spain's Almirall as a way to boost its European growth, according to Bloomberg.

Established product sales lacking in pharma's whopper M&A year

2014 may have been a banner year in pharma M&A, but for companies looking to sell off their portfolios of aging meds, it wasn't quite big enough.

Salix investors pushing for sale once supply issues wrap

Salix is working quickly to get some inventory issues under control after bidding farewell to its CFO and launching an audit committee review. But as soon as it does, some shareholders want the North Carolina drugmaker to put itself on the block.

Roche boosts its antibody arsenal with a $489M buyout

Roche is betting big on antibodies that can attack two targets at once, signing on to buy Austria's Dutalys for as much as $488.8 million and get its hands on some proprietary technology.

Flush-with-cash Shire revisits deal for NPS Pharma

Armed with a $1.64 billion breakup fee from former merger partner AbbVie and a brand-new $2.1 billion revolving loan facility, Shire looks ready to strike a deal. Rumor says it's revisiting some of its old targets, including New Jersey's NPS Pharmaceuticals.

Imaging specialist Varian to increase software focus with purchase of MeVis

Mobile medical apps are all the rage, but software is growing in importance in traditional medical devices too, as evidenced by Varian Medical Systems announcement that it will acquire Germany's MeVis Medical Solutions AG, a provider of software for cancer imaging.

UPDATED: Merck beefs up its cancer drug pipeline in $375M OncoEthix buyout

Further beefing up its rapidly growing pipeline for new cancer drugs, Merck has stepped in to buy out Switzerland's OncoEthix in a deal worth upward of $375 million. And the Big Pharma player is paying a hefty premium for a BET inhibitor that was in-licensed from Mitsubishi Tanabe just two years ago.

Philips shells out $1.2B for Volcano to gain ground in imaging therapy

Philips is shelling out $1.2 billion for San Diego devicemaker Volcano to gain ground in catheter-based imaging and beef up its offerings as it refocuses on its new healthcare business.

New Actavis chief sweeps aside most top Allergan execs

Combining Actavis and Allergan will be no easy task, but the companies think their new leadership team can get the job done. Tuesday, they announced a supporting cast for CEO Brent Saunders, who will play the lead role in his biggest challenge yet.

Med tech M&A deal value up 6-fold in 2014

This has been a good year for M&A in the medical device industry. The number of deals rose 39% to 57 announced transactions. Moreover, deal value more than sextupled to $86 billion, up from $14 billion in 2013.